![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Saturday, September 02, 2017 9:24:28 AM
https://static1.squarespace.com/static/5715352e20c647639137f992/t/583f7f14bebafbe20767391b/1480556310644/Prurisol-Presentation-for-Med-Derm-RD-Workshop_19Sep2016-u.pdf
Look at the graph on the right side of the page
For the Prurisol 200 mg (Per Protocol Population)
65% of this cohort started at IGA 3 (moderate psoriasis)
By 6 weeks into the trial those patients taking 100 mg of Prurisol twice per day per protocol those patients originally classified as IGA 3 (moderate) dropped from 65% to 30% that is a 35% drop in just 6 weeks. During the same 6 week period those patients classified as IGA 2 (mild psoriasis) increased from 35% to 50% a 15% increase (apparently 15% of the population moved from IGA 3 (moderate) to IGA 2 (mild)). During the same 6 week period those classified as IGA 1 (almost clear) increased from 0% to 20%.
By just 8 weeks into the trial those classified as either IGA 1 (almost clear) or IGA 0 (clear) increased from zero percent at the start of the trial to 40% after just 8 weeks from the start of the trial for those taking 100 mg of Prurisol twice per day per protocol.
By just 12 weeks into the trial those classified as either IGA 1 (almost clear) or IGA 0 (clear) increased from zero percent at the start of the trial to 55% after just 12 weeks from the start of the trial for those taking 100 mg of Prurisol every 12 hours per protocol.
The current trial doses are 1.5 and 2 times the 100 mg of Prurisol twice per day per protocol form the previous trial.
Good luck and GOD bless,
George
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM